PURPOSE: We have investigated the impact of particle size on the biodistribution, tumor uptake and antiproliferative efficacy of 5-FU-loaded liposomes. METHODS: Three different batches of pegylated liposomes varying in size (i.e., 70, 120 and 250 nm respectively) were tested. The active compounds encapsulated were an equimolar mix of 5-FU, 2'-deoxyinosine and folinic acid. Liposomes were subsequently tested on the human breast cancer model MDA231 cells, a model previously found to be resistant to 5-FU. In vitro, antiproliferative efficacy and microscopy studies of liposomes uptake were carried out. In vivo, comparative biodistribution and efficacy studies were performed in tumor-bearing mice. RESULTS: Difference in size did not change in vitro antiproliferative activity. Fluorescence-Microscopy studies showed that liposomes were mainly uptaken by tumor cells through a direct internalization process, regardless of their size. Biodistribution profiles in tumor-bearing mice revealed higher accumulation of small liposomes in tumors throughout time as compared with normal and large liposomes (p < 0.05). Additionally, we observed that the bigger were the tumors, the more vascularised they were and the greater was the difference in accumulation between small and large liposomes. Consequently, in vivo efficacy studies showed at study conclusion that a 68% reduction in tumor size was achieved with small liposomes (p < 0.05), whereas larger liposomes failed to reduce significantly tumor growth. Similarly, at study conclusion a trend towards higher survival-rate in animals treated with smaller liposomes was observed. CONCLUSION: This study suggests that particle size is critical to achieve higher selectivity and efficacy in experimental oncology, including in resistant tumors.
PURPOSE: We have investigated the impact of particle size on the biodistribution, tumor uptake and antiproliferative efficacy of 5-FU-loaded liposomes. METHODS: Three different batches of pegylated liposomes varying in size (i.e., 70, 120 and 250 nm respectively) were tested. The active compounds encapsulated were an equimolar mix of 5-FU, 2'-deoxyinosine and folinic acid. Liposomes were subsequently tested on the humanbreast cancer model MDA231 cells, a model previously found to be resistant to 5-FU. In vitro, antiproliferative efficacy and microscopy studies of liposomes uptake were carried out. In vivo, comparative biodistribution and efficacy studies were performed in tumor-bearing mice. RESULTS: Difference in size did not change in vitro antiproliferative activity. Fluorescence-Microscopy studies showed that liposomes were mainly uptaken by tumor cells through a direct internalization process, regardless of their size. Biodistribution profiles in tumor-bearing mice revealed higher accumulation of small liposomes in tumors throughout time as compared with normal and large liposomes (p < 0.05). Additionally, we observed that the bigger were the tumors, the more vascularised they were and the greater was the difference in accumulation between small and large liposomes. Consequently, in vivo efficacy studies showed at study conclusion that a 68% reduction in tumor size was achieved with small liposomes (p < 0.05), whereas larger liposomes failed to reduce significantly tumor growth. Similarly, at study conclusion a trend towards higher survival-rate in animals treated with smaller liposomes was observed. CONCLUSION: This study suggests that particle size is critical to achieve higher selectivity and efficacy in experimental oncology, including in resistant tumors.
Authors: J Ciccolini; L Peillard; A Evrard; P Cuq; C Aubert; A Pelegrin; P Formento; G Milano; J Catalin Journal: Clin Cancer Res Date: 2000-04 Impact factor: 12.531
Authors: E T Dams; P Laverman; W J Oyen; G Storm; G L Scherphof; J W van Der Meer; F H Corstens; O C Boerman Journal: J Pharmacol Exp Ther Date: 2000-03 Impact factor: 4.030
Authors: M C Alley; D A Scudiero; A Monks; M L Hursey; M J Czerwinski; D L Fine; B J Abbott; J G Mayo; R H Shoemaker; M R Boyd Journal: Cancer Res Date: 1988-02-01 Impact factor: 12.701
Authors: Theresa M Allen; Wilson W K Cheng; Jennifer I Hare; Kimberley M Laginha Journal: Anticancer Agents Med Chem Date: 2006-11 Impact factor: 2.505
Authors: Tyson Smyth; Max Kullberg; Noeen Malik; Peter Smith-Jones; Michael W Graner; Thomas J Anchordoquy Journal: J Control Release Date: 2014-12-16 Impact factor: 9.776
Authors: A Rodallec; C Franco; S Robert; G Sicard; S Giacometti; B Lacarelle; F Bouquet; A Savina; R Lacroix; F Dignat-George; J Ciccolini; P Poncelet; R Fanciullino Journal: Sci Rep Date: 2020-03-05 Impact factor: 4.379
Authors: Anne Rodallec; Jean-Michel Brunel; Sarah Giacometti; Helene Maccario; Florian Correard; Eric Mas; Caroline Orneto; Ariel Savina; Fanny Bouquet; Bruno Lacarelle; Joseph Ciccolini; Raphaelle Fanciullino Journal: Int J Nanomedicine Date: 2018-06-18